Highest-materiality recent filing
Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029
Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.
Azenta appoints Trey Martin as Multiomics President; Ginger Zhou steps down
Trey Martin appointed President of Multiomics effective April 6, 2026; reports to CEO John Marotta.
Thelema informed Azenta on March 27, 2026 that financing for the B Medical Systems acquisition has not been secured.
Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint
Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.
Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance
Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).
Director Alan P. Malus resigns from Azenta Board effective Jan 29, 2026
Malus resigned due to full-time commitments at another company.
Azenta stockholders elect directors, approve equity plan amendment and say-on-pay
All 10 director nominees elected; Dipal Doshi received 32,984,474 votes for.
Azenta sells B Medical Systems to related-party Thelema for $63M; close by Mar 31, 2026
Sale of B Medical Systems subsidiary to Thelema S.À R.L. for USD 63M; Thelema is majority-owned by Azenta VP & B Medical CEO Luc Provost.
Azenta authorizes $250M share repurchase program through 2028
Board authorized repurchase of up to $250M of common stock, effective Dec 9, 2025 through Dec 31, 2028.
Azenta Q4 revenue $159M, +6% YoY; FY2026 guidance 3-5% organic growth, margin expansion 300 bps
Q4 revenue $159M, +6% YoY (organic +4%); FY revenue $594M, +4% (organic +3%).
Azenta Q3 revenue flat at $144M; non-GAAP EPS $0.19 vs $0.14 YoY; reaffirms FY2025 guidance
Revenue $144M flat YoY; organic revenue down 2%. Sample Management Solutions -4%, Multiomics +4%.
Azenta VP and Chief Accounting Officer Violetta Hughes resigns effective Aug 6, 2025
Violetta Hughes, VP and Chief Accounting Officer, voluntarily resigns effective August 6, 2025.
Azenta GC Jason Joseph departs; Ephraim Starr appointed as General Counsel
Jason W. Joseph to cease as SVP, General Counsel & Secretary on May 15, 2025; employment ends June 30, 2025.
Azenta Q2 revenue $143M up 5% YoY; reaffirms FY2025 guidance
Revenue $143M (+5% YoY, organic +6%); Sample Mgmt Solutions $80M (+8%), Multiomics $64M (+2%).
Azenta President of Sample Management Solutions David Wang departs; consultant role through Dec 9
President of Sample Management Solutions David Wang's employment ends April 9, 2025; consulting period runs through December 9, 2025.
Azenta Q1 FY25 revenue rises 4% YoY to $148M; adjusted EBITDA margin improves 400 bps to 9.0%
GAAP diluted EPS from continuing ops -$0.21 (vs -$0.13 YoY); total diluted EPS -$0.29 (vs -$0.28).
For FY2024 (12 months ended Sep 30, 2024), continuing ops revenue $573.2M, operating loss $50.6M.
Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO
FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.
Azenta appoints Cornog, Koffey, Malus to board; forms Value Creation Committee
Appoints William Cornog (ex-KKR Capstone), Alan Malus (ex-Thermo Fisher EVP), and activist Quentin Koffey (Politan, 9.4% owner) as independent directors.
Azenta appoints John Marotta as President and CEO; Schwartz retires after 14-year tenure
John Marotta becomes President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz.
Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).
Azenta CEO Stephen Schwartz retiring; board initiates search for successor
Dr. Schwartz retires as CEO and director effective May 7, 2024; will continue until successor appointed.
Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower
Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.
On May 15, 2025, the Company appointed Ephraim Starr as its Senior Vice President, General Counsel and Secretary to succeed Mr. Joseph.
On May 12, 2025, Azenta, Inc. (the “Company”) and Jason W. Joseph, Senior Vice President, General Counsel and Secretary, agreed that Mr. Joseph would cease to serve in that role, effective May 15, 2025 and that Mr. Joseph’s employment with the Company would cease effective June 30, 2025.
On April 7, 2025, Azenta, Inc. (the “Company”) and David Wang, President of Sample Management Solutions, agreed that Mr. Wang’s employment with the Company would cease effective April 9, 2025
Herman Cueto, who is departing from his role at the Company.
appointed Lawrence Lin as its Executive Vice President and Chief Financial Officer, effective as of Effective Time
Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.
Pursuant to the Cooperation Agreement, on November 1, 2024, the Board appointed Mr. Koffey as a member of the Board, effective November 1, 2024, with an initial term expiring at the 2025 Annual Meeting.
Effective November 1, 2024, the Board appointed each of Mr. Cornog and Mr. Malus (together with Mr. Koffey, the “New Directors”) as a member of the Board, with an initial term expiring at the 2025 Annual Meeting.
the Board also increased the size of the Board from eight to nine members and appointed Mr. Marotta as a member of the Board
succeed the Company’s current President and Chief Executive Officer, Dr. Stephen Schwartz, who as previously announced is retiring effective as of the Start Date
Dr. Schwartz resigned as a director of the Company effective as of May 7, 2024
Dr. Stephen Schwartz informed the Company of his intention to retire from his position as President and Chief Executive Officer and a director of the Company
Max materiality 0.85 · Median 0.70 · Most common event earnings